Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/1B Open-Label, Dose-Escalation Study of APVO436 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndrome (MDS)

Trial Profile

Phase 1/1B Open-Label, Dose-Escalation Study of APVO436 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndrome (MDS)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2019

At a glance

  • Drugs APVO-436 (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Aptevo Therapeutics
  • Most Recent Events

    • 13 Dec 2018 According to an Aptevo Therapeutics media release, top-line data are anticipated in late 2019.
    • 13 Dec 2018 Status changed from not yet recruiting to recruiting, according to an Aptevo Therapeutics media release.
    • 13 Dec 2018 According to an Aptevo Therapeutics media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top